Tarsus Pharmaceuticals, Inc.

NASDAQ:TARS

Biotechnology

Healthcare
$75.95 +0.46%

+$0.29 today

Market cap
$3.74B
Beta
0.51
P/E (TTM)
-55.9
EPS (TTM)
-$1.12
52W Low $38.51High $85.25

Volume 0.45M

Average 0.61M

TARS Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Tarsus Pharmaceuticals, Inc.NASDAQ: TARS

Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026

Stock-based compensation growth accelerates

Q3 FY2026 stock-based compensation of $27.22M rose 122.3% year over year, ahead of the +91.9% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 104.8% from the prior quarter. Over 3 fiscal years it compounded at +45.8% a year.

Context

  • Stock-based compensation amounted to 9.2% of revenue in FY2025, down 6.0 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +122.3% holds above the trailing-twelve-month pace of +91.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$27.22M+104.8% QoQ
Last fiscal yearDec 2025
$41.72M+50.0% YoY
LTMSep 2026
$66.79M+91.9% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+122.3%——
1 year+50.0%——
3-year CAGR+45.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
41.72M USD
Year-over-year change
+50.0%
4-year CAGR
+49.0%

Stock-Based Compensation vs competitors

How TARS compares with its peers on the latest reported figures

  • TARS's LTM Sep 2026 stock-based compensation of $66.79M is the largest of the 6 companies compared; the peer median is $3.19M.
  • Its year-over-year change of +91.9% is the highest of 4, against a peer median of -34.6%.
  • Stock-based compensation amounts to 9.8% of revenue for TARS, versus a peer median of 9.0%.
TARS Competitors Peer median
Stock-Based Compensation for TARS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TARSTarsus Pharmaceuticals, Inc.LTM Sep 2026$66.79M +91.9%+45.8%9.8%
ARQTArcutis Biotherapeutics, Inc.LTM Jun 2026$43.55M +10.4%+7.3%9.4%
HROWHarrow Health, Inc.LTM Mar 2026$11.78M -34.6%+16.2%4.4%
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026$3.19M -47.9%-12.7%8.6%
SLGLSol-Gel Technologies Ltd.LTM Jun 2024$2.13M ——32.5%
TTRXTurn Therapeutics Inc.LTM Mar 2026$0 ———
Peer median (excluding TARS) $3.19M-34.6%+7.3%9.0%

Competitors are the stored peer set for TARS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(13.83M)(62.09M)(135.89M)(115.55M)(66.42M)
Depreciation & Amortization312K326K877K1.23M1.82M
Deferred Income Tax00000
Stock-Based Compensation8.46M13.46M19.83M27.82M41.72M
Change in Working Capital1.37M(951K)306K3.84M14.64M
Accounts Receivables(73K)(3.49M)(14.13M)(30.14M)(39.05M)
Inventory03.49M(3.11M)(2.05M)(1.75M)
Accounts Payables3.88M821K13.24M40.34M6.91M
Other Working Capital(2.44M)(1.77M)4.3M(4.31M)48.53M
Other Non-Cash Items7.44M226K(2.61M)(360K)(4.21M)
Operating Cash Flow3.75M(49.03M)(117.49M)(83.03M)(12.45M)
Capital Expenditures(586K)(506K)(5.5M)(1.57M)(9.86M)
Acquisitions (Net)0144.12M000
Purchases of Investments0(149.44M)(28.66M)(265.63M)(394.06M)
Sales of Investments05.32M174.77M73M361.8M
Other Investing Activities0(144.12M)(4M)(5M)0
Investing Cash Flow(586K)(144.63M)140.6M(199.2M)(42.12M)
Debt Repayment019.13M10M39.6M0
Common Stock Issued21K74.86M120.18M115.06M143.39M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow21K93.99M130.18M154.66M143.39M
Effect of Forex Changes00000
Net Change in Cash3.18M(99.67M)153.29M(127.57M)88.82M
Free Cash Flow3.16M(49.54M)(123M)(84.59M)(22.31M)

Tarsus Pharmaceuticals, Inc.

NASDAQ:TARS

Intrinsic Alpha fair value

Locked

Current Price

$75.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.